Combination Therapy With Ceftriaxone and Lansoprazole, Acquired Long QT Syndrome, and Torsades de Pointes Risk
We read with great interest the paper by Lorberbaum et al. (1) recently published in the Journal, in which evidence was provided that ceftriaxone plus lansoprazole combination therapy (CFX+LSZ) was unexpectedly associated with an increased risk of acquired long QT syndrome (aLQTS); thus, it is also...
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 2017-04, Vol.69 (14), p.1876-1877 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1877 |
|---|---|
| container_issue | 14 |
| container_start_page | 1876 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 69 |
| creator | Lazzerini, Pietro Enea, MD Bertolozzi, Iacopo, MD Rossi, Marco, PharmD Capecchi, Pier Leopoldo, MD Laghi-Pasini, Franco, MD |
| description | We read with great interest the paper by Lorberbaum et al. (1) recently published in the Journal, in which evidence was provided that ceftriaxone plus lansoprazole combination therapy (CFX+LSZ) was unexpectedly associated with an increased risk of acquired long QT syndrome (aLQTS); thus, it is also theoretically associated with Torsades de Pointes (TdP) and sudden cardiac death. We report on 2 clinical observations that possibly further support these findings. |
| doi_str_mv | 10.1016/j.jacc.2016.11.090 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1885945939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0735109717305715</els_id><sourcerecordid>1885945939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-666a34885f4af187a3e17c4e98434b127c9c7c276bdeb6c45f885709a8f230743</originalsourceid><addsrcrecordid>eNp9ktFr1TAUxoMo7jr9B3yQgC8-2C5pmqYBGYyL24QLU3fFx5Cmpy5dm9wlrez615typ8IefMoh-Z2Pk-87CL2mJKeEVid93mtj8iLVOaU5keQJWlHO64xxKZ6iFRGMZ5RIcYRexNgTQqqayufoqKhZzRmVK-TWfmys05P1Dm9vIOjdHn-30w1eQzcFq--9A6xdizfaRb8L-pcf4D0-M3ezDZCuvfuBv2zx9d61wY_paYG3PkTdQsQt4M_euimVX228fYmedXqI8OrhPEbfzj9u15fZ5uri0_psk5mSySmrqkqzsq55V-qO1kIzoMKUIOuSlQ0thJFGmEJUTQtNZUreJVYQqeuuYESU7Bi9O-jugr-bIU5qtNHAMGgHfo6KJl6WXDKZ0LeP0N7PwaXpEiU5SXKVSFRxoEzwMQbo1C7YUYe9okQtaaheLWmoJQ1FqUpppKY3D9JzM0L7t-WP_Qn4cAAgefHTQlDRWHAG2uStmVTr7f_1Tx-1m8E6a_RwC3uI__6hYqGIul72YVkHKhjhgnL2G4L5rps</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1895007467</pqid></control><display><type>article</type><title>Combination Therapy With Ceftriaxone and Lansoprazole, Acquired Long QT Syndrome, and Torsades de Pointes Risk</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Lazzerini, Pietro Enea, MD ; Bertolozzi, Iacopo, MD ; Rossi, Marco, PharmD ; Capecchi, Pier Leopoldo, MD ; Laghi-Pasini, Franco, MD</creator><creatorcontrib>Lazzerini, Pietro Enea, MD ; Bertolozzi, Iacopo, MD ; Rossi, Marco, PharmD ; Capecchi, Pier Leopoldo, MD ; Laghi-Pasini, Franco, MD</creatorcontrib><description>We read with great interest the paper by Lorberbaum et al. (1) recently published in the Journal, in which evidence was provided that ceftriaxone plus lansoprazole combination therapy (CFX+LSZ) was unexpectedly associated with an increased risk of acquired long QT syndrome (aLQTS); thus, it is also theoretically associated with Torsades de Pointes (TdP) and sudden cardiac death. We report on 2 clinical observations that possibly further support these findings.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2016.11.090</identifier><identifier>PMID: 28385319</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antibiotics ; Cardiac arrhythmia ; Cardiology ; Cardiovascular ; Ceftriaxone ; Combination therapy ; Data Mining ; Drug Interactions ; Drug therapy ; Electrocardiography ; Health risks ; Heart diseases ; Humans ; Internal Medicine ; Lansoprazole ; Long QT Syndrome ; Patients ; Side effects ; Therapy ; Torsades de Pointes</subject><ispartof>Journal of the American College of Cardiology, 2017-04, Vol.69 (14), p.1876-1877</ispartof><rights>American College of Cardiology Foundation</rights><rights>2017 American College of Cardiology Foundation</rights><rights>Copyright Elsevier Limited Apr 11, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-666a34885f4af187a3e17c4e98434b127c9c7c276bdeb6c45f885709a8f230743</citedby><cites>FETCH-LOGICAL-c439t-666a34885f4af187a3e17c4e98434b127c9c7c276bdeb6c45f885709a8f230743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jacc.2016.11.090$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28385319$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lazzerini, Pietro Enea, MD</creatorcontrib><creatorcontrib>Bertolozzi, Iacopo, MD</creatorcontrib><creatorcontrib>Rossi, Marco, PharmD</creatorcontrib><creatorcontrib>Capecchi, Pier Leopoldo, MD</creatorcontrib><creatorcontrib>Laghi-Pasini, Franco, MD</creatorcontrib><title>Combination Therapy With Ceftriaxone and Lansoprazole, Acquired Long QT Syndrome, and Torsades de Pointes Risk</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>We read with great interest the paper by Lorberbaum et al. (1) recently published in the Journal, in which evidence was provided that ceftriaxone plus lansoprazole combination therapy (CFX+LSZ) was unexpectedly associated with an increased risk of acquired long QT syndrome (aLQTS); thus, it is also theoretically associated with Torsades de Pointes (TdP) and sudden cardiac death. We report on 2 clinical observations that possibly further support these findings.</description><subject>Antibiotics</subject><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Cardiovascular</subject><subject>Ceftriaxone</subject><subject>Combination therapy</subject><subject>Data Mining</subject><subject>Drug Interactions</subject><subject>Drug therapy</subject><subject>Electrocardiography</subject><subject>Health risks</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Lansoprazole</subject><subject>Long QT Syndrome</subject><subject>Patients</subject><subject>Side effects</subject><subject>Therapy</subject><subject>Torsades de Pointes</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ktFr1TAUxoMo7jr9B3yQgC8-2C5pmqYBGYyL24QLU3fFx5Cmpy5dm9wlrez615typ8IefMoh-Z2Pk-87CL2mJKeEVid93mtj8iLVOaU5keQJWlHO64xxKZ6iFRGMZ5RIcYRexNgTQqqayufoqKhZzRmVK-TWfmys05P1Dm9vIOjdHn-30w1eQzcFq--9A6xdizfaRb8L-pcf4D0-M3ezDZCuvfuBv2zx9d61wY_paYG3PkTdQsQt4M_euimVX228fYmedXqI8OrhPEbfzj9u15fZ5uri0_psk5mSySmrqkqzsq55V-qO1kIzoMKUIOuSlQ0thJFGmEJUTQtNZUreJVYQqeuuYESU7Bi9O-jugr-bIU5qtNHAMGgHfo6KJl6WXDKZ0LeP0N7PwaXpEiU5SXKVSFRxoEzwMQbo1C7YUYe9okQtaaheLWmoJQ1FqUpppKY3D9JzM0L7t-WP_Qn4cAAgefHTQlDRWHAG2uStmVTr7f_1Tx-1m8E6a_RwC3uI__6hYqGIul72YVkHKhjhgnL2G4L5rps</recordid><startdate>20170411</startdate><enddate>20170411</enddate><creator>Lazzerini, Pietro Enea, MD</creator><creator>Bertolozzi, Iacopo, MD</creator><creator>Rossi, Marco, PharmD</creator><creator>Capecchi, Pier Leopoldo, MD</creator><creator>Laghi-Pasini, Franco, MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20170411</creationdate><title>Combination Therapy With Ceftriaxone and Lansoprazole, Acquired Long QT Syndrome, and Torsades de Pointes Risk</title><author>Lazzerini, Pietro Enea, MD ; Bertolozzi, Iacopo, MD ; Rossi, Marco, PharmD ; Capecchi, Pier Leopoldo, MD ; Laghi-Pasini, Franco, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-666a34885f4af187a3e17c4e98434b127c9c7c276bdeb6c45f885709a8f230743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antibiotics</topic><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Cardiovascular</topic><topic>Ceftriaxone</topic><topic>Combination therapy</topic><topic>Data Mining</topic><topic>Drug Interactions</topic><topic>Drug therapy</topic><topic>Electrocardiography</topic><topic>Health risks</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Lansoprazole</topic><topic>Long QT Syndrome</topic><topic>Patients</topic><topic>Side effects</topic><topic>Therapy</topic><topic>Torsades de Pointes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lazzerini, Pietro Enea, MD</creatorcontrib><creatorcontrib>Bertolozzi, Iacopo, MD</creatorcontrib><creatorcontrib>Rossi, Marco, PharmD</creatorcontrib><creatorcontrib>Capecchi, Pier Leopoldo, MD</creatorcontrib><creatorcontrib>Laghi-Pasini, Franco, MD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lazzerini, Pietro Enea, MD</au><au>Bertolozzi, Iacopo, MD</au><au>Rossi, Marco, PharmD</au><au>Capecchi, Pier Leopoldo, MD</au><au>Laghi-Pasini, Franco, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination Therapy With Ceftriaxone and Lansoprazole, Acquired Long QT Syndrome, and Torsades de Pointes Risk</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>2017-04-11</date><risdate>2017</risdate><volume>69</volume><issue>14</issue><spage>1876</spage><epage>1877</epage><pages>1876-1877</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>We read with great interest the paper by Lorberbaum et al. (1) recently published in the Journal, in which evidence was provided that ceftriaxone plus lansoprazole combination therapy (CFX+LSZ) was unexpectedly associated with an increased risk of acquired long QT syndrome (aLQTS); thus, it is also theoretically associated with Torsades de Pointes (TdP) and sudden cardiac death. We report on 2 clinical observations that possibly further support these findings.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28385319</pmid><doi>10.1016/j.jacc.2016.11.090</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2017-04, Vol.69 (14), p.1876-1877 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1885945939 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antibiotics Cardiac arrhythmia Cardiology Cardiovascular Ceftriaxone Combination therapy Data Mining Drug Interactions Drug therapy Electrocardiography Health risks Heart diseases Humans Internal Medicine Lansoprazole Long QT Syndrome Patients Side effects Therapy Torsades de Pointes |
| title | Combination Therapy With Ceftriaxone and Lansoprazole, Acquired Long QT Syndrome, and Torsades de Pointes Risk |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T11%3A59%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20Therapy%20With%20Ceftriaxone%20and%20Lansoprazole,%20Acquired%20Long%20QT%20Syndrome,%20and%20Torsades%20de%20Pointes%20Risk&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Lazzerini,%20Pietro%20Enea,%20MD&rft.date=2017-04-11&rft.volume=69&rft.issue=14&rft.spage=1876&rft.epage=1877&rft.pages=1876-1877&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/j.jacc.2016.11.090&rft_dat=%3Cproquest_cross%3E1885945939%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1895007467&rft_id=info:pmid/28385319&rft_els_id=1_s2_0_S0735109717305715&rfr_iscdi=true |